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PURPOSE. To evaluate the ability of total and macular estimated retinal ganglion cell (RGC)
counts to discriminate between healthy and glaucomatous eyes. To determine threshold
markers of the estimated RGCs taking into account age dependence.
METHODS. This was a cross-sectional, observational study. The study group consisted of 176
eyes subdivided in three groups: 32 healthy, 91 preperimetric (PPG), and 53 primary open-
angle glaucoma (POAG) eyes. The estimate of total and macular number of RGCs was
obtained using a model described later. To account for the inverse correlation of RGC count
with age, we considered two age subgroups (55 and >55 years) for both total and macular
estimated RGC counts. We computed frequency distributions and receiver operating
characteristic (ROC) curves to measure the discriminating ability and derive the cut-offs
between two different conditions with their relative diagnostic parameters.
RESULTS. The total and macular estimated RGC counts showed highly significant differences
among the three groups (P < 0.0001). The estimated RGC counts performed fairly well in
distinguishing healthy from glaucomatous (PPGþPOAG) eyes (area under the curve [AUC] ¼
0.79–0.92) with no statistically significant difference between total and macular RGCs. The
approach allowed a good discrimination also between PPG and POAG eyes (AUC ¼ 0.86–
0.92). Cutoffs for the older age bracket were found to be lower in all cases.
CONCLUSIONS. Retinal ganglion cell counts estimated with empirical formulas with RTVue-100
could be used as a valid surrogate for neural losses in glaucoma.
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Glaucoma is an optic neuropathy, deriving from progressiveretinal ganglion cells (RGC) loss, that causes thinning of
retinal nerve fiber layer (RNFL) and progressive appearance of
visual field defects.1 Perimetry is currently used for diagnosis
and staging of disease, but many studies showed that structural
changes precede the loss of visual function and that a
considerable number of RGCs is lost before the disease
becomes clinically relevant.2–8 For this reason, optical coher-
ence tomography (OCT), enabling visualization of the retinal
layers similar to the histologic appearance, is more and more
frequently used to identify structural changes in the early stages
of the disease. Recently, measurements of structural and
functional tests were combined into empirical formulas for
the estimation of RGCs.9–12 A direct quantification of RGCs is
not applicable in vivo, but it is possible to estimate the number
of RGCs from empirical formulas combining standard automat-
ed perimetry (SAP) sensitivities and measurements of RNFL
thickness by OCT.9,10 These formulas have shown a valid
correlation with histologic counts in monkeys’ retinas in
experimental glaucoma models.9 These estimates seem to
perform better than functional and structural parameters
considered separately, both for staging and monitoring the
disease.10–14
The previously demonstrated involvement of the macula15
in early glaucoma is compatible with the fact that the macula is
the retinal region with the highest density of RGCs.16,17 As a
matter of fact, 50% or more of total RGCs are contained within
168 of the foveal center, a region that represents 7.3% of the
total retina.18 The estimated count of the macular RGC number
could be a useful parameter to identify the presence of
glaucomatous damage.
The clinical applications of estimated RGC counts for
glaucoma diagnosis have been published before.10–14 We
investigated a possible role of the estimated RGC count as a
biomarker that is an objectively measurable feature with the
ability to predict the risk of a disease,19 or to indicate a
pathologic biological process20 when its value is beyond a
certain threshold. As regards to glaucomatous optic neuropa-
thy, such a biomarker could be used to identify patients with a
higher risk of having glaucoma and to distinguish between the
various stages of the disease.
The primary goal of this study was to evaluate the ability of
total and macular estimated RGC counts to discriminate
between healthy and glaucomatous eyes and between eyes in
various stages of glaucomatous disease. The secondary goal was
to determine threshold markers of the estimated RGC count
taking into account the impact of aging.
METHODS
This cross-sectional observational study was conducted at the
Glaucoma Center of the Eye Clinic, Department of Surgical
Sciences, University of Torino, Italy. The methods were applied
in accordance to the tenets of the Declaration of Helsinki;
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informed consent was obtained from all subjects and the Ethics
Committee (University & General Hospital San Giovanni
Battista of Torino) gave approval.
To be included in the study, participants had to meet the
following criteria: age between 18 and 80 years, best-corrected
visual acuity (BCVA) greater than or equal to 20/30, spherical
equivalent greater than5.0 diopters (D) and less thanþ3.0 D,
and open angle on gonioscopy. Subjects with ocular surgery,
retinal or macular pathology, or systemic or neurologic condi-
tions that could produce visual field defects, were excluded.
All subjects underwent a comprehensive ophthalmic
examination consisting of: BCVA, ultrasound pachymetry, slit-
lamp biomicroscopy of anterior and posterior segment, Gold-
mann applanation tonometry (GAT), diurnal tonometric curve,
gonioscopy, peripapillary, and macular imaging using Fourier
Domain-OCT (FD-OCT RTVue-100 software version A4, 5, 0,
59; Optovue, Fremont, CA, USA). SAP was performed with
Swedish Interactive Threshold Algorithm (SITA) Standard
strategy, program 24-2 of the Humphrey Field Analyzer (HFA;
Carl Zeiss Meditec, Jena, Germany). Fixation losses less than or
equal to 20%, false positives and false negatives less than or
equal to 33% were established as the reliability criteria.
The study included three groups of subjects: PPG,
glaucomatous, and a control group recruited from the healthy
population. The latter were required to have no family history
of glaucoma, highest daily IOP less than 21 mm Hg, a normal
visual field (VF) test and a normal optic nerve head (ONH)
appearance. Patients affected by PPG had the highest daily IOP
greater than 21 mm Hg, normal VF test, and ONH changes
(cup–disc ratio alteration, disc hemorrhages, rim notching,
diffused or localized RNFL defects). Primary open-angle
glaucoma (POAG) was diagnosed based on the presence of
highest daily IOP greater than 21 mm Hg, abnormal VF
according to Hodapp-Parrish-Anderson criteria for diagnosing
glaucomatous damage,21 and glaucomatous optic disc changes.
Optic nerve head appearance was evaluated by slit-lamp
biomicroscopy of the posterior segment using a 78-D lens.
FD-OCT RTVue-100
The Glaucoma Protocol of FD-OCT RTVue-100 was used to
acquire RNFL thickness measurements. All scans were
repeated three times by the same operator. The RNFL
thicknesses used for the analysis derived from the scan with
the highest signal strength index (SSI).
Optic nerve head scans consist of 13 circle lines with a
diameter of 1.3 to 4.9 mm centered on the optic disc. These
lines were used to create a peripapillary nerve fiber layer
thickness (RNFL) map while 12 radial lines with 3.7-mm length
were used to determine morphologic parameters of disc
margin. This scan was used to calculate average, average–
superior, and average–inferior RNFL thicknesses.
The three-dimensional (3D) disc protocol was used to
identify the optic disc margin to obtain RNFL measurement. It
consists of a 53 5 mm square region with 101 horizontal lines
and a total of 51,813 A-scans.
Scans with motion artifacts and with signal strength index
less than 45 were excluded.
Estimate of Retinal and Macular Ganglion Cell
Count
The estimated of RGC count was obtained by applying the
model developed and described in detail by Medeiros et
al.10–12,22 based on the empirical formulas processed by
Harwerth et al.9 In this model, data from structural and
functional tests are elaborated to derive a final estimate of the
RGC count. The number of RGC somas in a retinal area
corresponding to a specific SAP test field location at
eccentricity (ec) with sensitivity (s) in dB is estimated though
the following formula:
m ¼ 0:0543ðec3 1:32Þ½  þ 0:9 ð1Þ
b ¼ 1:53ðec3 1:32Þ½   14:8 ð2Þ
gc ¼ ðs 1Þ  b½ 
m
 
þ 4:7 ð3Þ
SAPrgc ¼ R10ðgc3 0:1Þ ð4Þ
In the formula, m and b represent the slope and the
intercept of the linear function describing the relationship
between the ganglion cell quantity (gc) in decibels and the VF s
in decibels at a given ec. The cell density obtained from each
perimetry measurement is supposed to be almost uniform over
a retinal region corresponding to an area of 68 3 68 of visual
space that separates test locations in SAP. The SAP-derived
estimated RGC count (SAPrgc) derives from the sum of the
estimates in all SAP locations.
The number of RGC axons is estimated using the RNFL
thickness measurement by OCT. The model considers the
effect of aging on axonal density. The estimated number of
RGC axons (OCTrgc) is obtained with the formula:
d ¼ ð0:0073 ageÞ þ 1:4 ð5Þ
c ¼ ð0:263MDÞ þ 0:12 ð6Þ
a ¼ average RNFL thickness3 108703d ð7Þ
OCTrgc ¼ 10 ðlogðaÞ3 10cÞ3 0:1½  ð8Þ
In the above formula, d is the axonal density (axons/lm2), c
is a correction factor for the severity of disease taking into
account remodeling of the RNFL axonal and nonaxonal
composition, and MD is the SAP mean deviation. These
formulas provide two estimates of the number of RGCs, one
from a functional source and one from a structural source.
Finally, the total estimated RGC count is obtained as:
Estimated total RGC count ¼ 1 þ MD
30
 
3OCTrgc
þ MD
30
 
3 SAPrgc ð9Þ
Estimated macular RGC count was calculated using the
following formulas22:
m ¼ 0:0543ðec3 1:32Þ½  þ 0:9 ð10Þ
b ¼ 1:53ðec3 1:32Þ½   14:8 ð11Þ
gc ¼ ðs 1Þ  b½ 
m
 
þ 4:7 ð12Þ
Macular SAPrgc ¼ R10ðgc3 0:1Þ ð13Þ
The formula for macular SAPrgc is the same used for total
RGCs estimate, but only 16 central points of the 24-2 SAP test
were used; they correspond to the central 108.
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Temporal peripapillary RNFL thickness measured by OCT is
entered in the following formula in order to estimate the
number of macular RGC axons:
d ¼ ð0:0073 ageÞ þ 1:4 ð14Þ
c ¼ ð0:263macular TDÞ þ 0:12 ð15Þ
a ¼ average temporal RNFL thickness3 0:53 108703d
ð16Þ
Macular OCTrgc ¼ 10 ðlogðaÞ3 10cÞ3 0:1½  ð17Þ
The macular total deviation (macular TD), used instead of
MD, corresponds to the average TD of the central 16 points of
24-2 SAP in decibels.22 Thus, the macular estimated RGC count
is obtained with the same formula used for total RGC count:
Estimated macular RGC count ¼ 1 þ MD
30
 
3Macular OCTrgc
þ MD
30
 
3Macular SAPrgc
ð18Þ
Statistical Analysis
Continuous variables were checked to meet the normality
conditions of Shapiro-Wilk test. Analysis of variance and
Fisher’s least significant difference (LSD) post hoc test with
Bonferroni adjustment were used for intergroup comparisons
for normally distributed variables. Dichotomic variables were
arranged in cross-correlation tables and studied with a v2 test
or Fisher exact test.
The study of the frequency distributions of the pathologic
and healthy global and macular estimated RGC count allowed
to compute the level-specific likelihood ratios (LR) defined as
the ratio of the frequency of the pathologic condition to the
frequency of the healthy one (or more severe to less severe):
the value of RGC count for which level-specific LR ¼ 1 marks
the border between dominance of one condition over the
other.
The frequency distributions were the basis for computing
the receiver operating characteristic (ROC) curve, that is the
plot of true positive rates (sensitivity; SNS) versus false positive
rates (1-specificity; SPC): the area under the curve (AUC) is the
standard parameter, which quantifies the ability of discrimi-
nating between two conditions, AUC¼ 0.5 being null (chance)
and then increasing from 0.6 (poor) to 1 (excellent).
The values of SNS and SPC characterizing each level of RGC
count allow deriving various parameters. They determine the
associated LR of a positive test LRþ ¼ SNS/(1-SPC) (i.e., the
likelihood that a positive test result would be expected in a
patient with disease compared with the likelihood that the
same result would be expected in a patient without disease).
Positive LRs, being the ratio of posttest odds to pretest odds,
allows to estimate the posttest probability after a diagnostic
test: LRþ greater than 1 produces a posttest probability of a
positive result for a target disorder, which is higher than the
pretest probability (i.e., rules in favor of disease). Sensitivity
and SPC also identify the most appropriate cutoff between the
two target conditions, through maximization of: (1) harmonic
mean (HM) of SNS and SPC, (2) Jouden’s index J¼SNSþSPC1,
and (3) Cohen’s kappa, and minimization of the distance of the
curve from the (0, 1) upper left vertex D¼((1SNS)2
þ(1SPC)2)0.5. This cutoff value is of course coincident with
the one identified by the frequency distributions in correspon-
dence to level specific LR¼ 1, but it has the added value of the
quantification of the discriminating ability.
Differences between the AUCs were tested for statistical
significance with the method of Hanley and McNeil.23
Correlation between continuous variables was estimated
using the Pearson linear coefficient and regression analysis.
Statistical significance was set at P less than or equal to
0.05. The SPSS program package version 19.0 (SPSS, Inc.,
Chicago, IL, USA) was used for statistical analysis.
RESULTS
The study group consisted of 176 eyes: 32 healthy, 91 PPG, and
53 POAG eyes. Demographic characteristics of the study
population are illustrated in Table 1.
The ANOVA and v2 test showed that the groups are
comparable for age, sex, visual acuity, and refraction.
Intraocular pressure has a lower mean value for POAG eyes
than for PPG eyes; this is justified by the fact that not every
PPG eye received antiglaucomatous therapy. As expected,
glaucomatous eyes have significantly worse VF MD than
healthy and PPG eyes (P < 0.0001), while there is no
TABLE 1. Comparison of the Demographic and Clinical Characteristics of Healthy Eyes, PPG, and POAG Eyes
Parameters Healthy PPG POAG P Value
Eyes (n) 32 91 53
Age (y) 54.34 (9.28) 55.6 (11.12) 57.40 (9.67) 0.31*
Sex (male/female) 10/22 30/61 21/32 0.67†
BCVA (decimal fraction) 0.93 (0.08) 0.94 (0.09) 0.91 (0.1) 0.14*
SE (D) 0.6 (1.62) 0.87 (2.11) 0.68 (1.96) 0.74*
IOP (mm Hg) 15.38 (2.01) 17.22 (2.70)‡ 16.26 (2.45) § 0.001*
MD (dB) 0.26 (0.72) 0.88 (1.28) 5.17 (3.91)‡§ <0.0001*
PSD (dB) 1.67 (0.41) 1.70 (0.35) 4.64 (2.61)‡§ <0.0001*
RNFL average (lm) 109.26 (9.23)§ 95.28 (10.65)‡ 83.22 (11.03)‡§ < 0.0001*
Estimated total RGC count 1,151,924 (113,441)§ 969,506 (162,907)‡ 654,706 (176,499)‡§ <0.0001*
Estimated macular RGC count 593,315 (65,834)§ 507,036 (75,685)‡ 352,047 (102,247)‡§ < 0.0001*
The parameters are expressed as mean and SD. SE, Spherical Equivalent; IOP (highest value of the diurnal tonometric curve); MD of SAP; PSD of
SAP.
* ANOVA.
† v2 test.
‡ Statistically significant difference from healthy eyes group (LSD post hoc test).
§ Statistically significant difference from PPG eyes group (LSD post hoc test).
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statistically significant difference between healthy and PPG
eyes in regard to the MD value (P ¼ 0.2).
The total and macular estimated RGCs show highly
significant differences among the three groups (P < 0.0001).
The estimated macular RGC counts represent approximately
52% of total RGC in healthy eyes, 53% in PPG eyes, and 54% in
POAG eyes. Compared with the estimated total number of
RGCs in healthy eyes, POAG eyes have 43% fewer estimated
RGCs and PPG eyes have 16% fewer total RGCs. Similar
proportions hold also for the mean macular estimated counts
(41% and 15%).
The estimated RGC number has a moderate but significant
linear inverse correlation with age in all three groups. For the
healthy group (the simplest case, where the only independent
variable is age and no other factors linked to the loss of RGCs)
we derived a Pearson’s coefficient r ¼0.46 (P ¼ 0.007) and
regression coefficient b¼5625 RGCs/year, corresponding to
a physiological average loss of approximately 50,000 to 60,000
total estimated RCG counts every 10 years.
On the average, it is thus to be expected that also the cutoff
between healthy and pathologic conditions will be affected by
the aging process. To check this point within the limits posed
by the individual peculiarities and the small sample size of the
healthy group, we considered two subgroups, using as divider
the median age of patients: 55 years or younger (healthy n ¼
24, PPG n¼ 39, POAG n¼ 10) and older than 55 years (healthy
n¼ 8, PPG n ¼ 52, POAG n¼ 43).
The Figure shows on the left the results for the total
estimated RGC count for patients older than 55 years when
testing the discriminating ability between healthy and glau-
comatous eyes (PPGþPOAG). The frequency distributions (Fig.
A) share a modest region of overlapping, reflected in the good
value of AUC (0.92) for the ROC curve (Fig. B). The four
methods for threshold determination (Fig. C) unanimously
confirm that the value RGC ¼ 900,000 is the most appropriate
threshold between glaucoma and not glaucoma (dotted line).
At cutoff, sensitivity is 100%, specificity 73% and the LR of
positive test LRþ is 3.7.
The results of the analogous procedures on the total
estimated RGC count for patients younger than 55 years are
shown in the first line of Table 2; the first two lines of Table 3
report all corresponding results for the macular estimated RGC
count.
In order to analyze also the capability of estimated RGC
count in differentiating between PPG and POAG eyes, we
repeated the analysis comparing the two PPG and POAG
groups. The results for patients older than 55 years are shown
on the right side of the Figure: frequency distributions (Fig. D),
ROC curve (Fig. E), and threshold determination (Fig. F). We
can see that AUC¼0.90 and the cutoff value is RGC¼800,000,
with 77% SNS, 88% SPC, and LRþ ¼ 6.6. The results of the
analogous procedures on the total estimated RGC count for
patients younger than 55 years, are shown in the third line of
Table 2; Table 3 reports all corresponding results for the
macular estimated RGC count. For completeness, the tables
report also the outcomes of the analysis on healthy versus PPG
and healthy versus POAG for both total and macular estimated
RGC counts.
Generally, the AUC values do not show significant
differences between macular and total estimated RGC; the
same is true also for the comparison between the two age
brackets.
DISCUSSION
In the present study, we explored the possibility of using
RGC counts estimated from structural and functional mea-
surements in distinguishing glaucomatous from healthy eyes
in an independent population. In fact, several studies dem-
onstrated that the use of a combined structure and function
measure to estimate RGC losses performed better than
isolated structural and functional parameters. The study car-
ried out by Medeiros et al.14 attested that estimated RGC
counts performed better than average RNFL thickness in
discriminating glaucomatous from healthy eyes (AUC 0.95 vs.
0.88, respectively). Zhang et al.22 outlined the superiority of
macular and total estimated RGC count in comparison to
macular ganglion cell-inner plexiform layer (mGCIPL) thick-
ness and RNFL thickness, respectively (AUC 0.87 vs. 0.78 for
macular parameters and 0.93 vs. 0.86 for total RNFL
parameters). Our study was based on these assumptions
and was meant as a validation of an established method for
estimating the RGC count using a different FD-OCT (RTVue-
100).
Our results indicated that the estimated RGC count of the
healthy eyes group (1,151,924 6 113,441) was consistent with
the number of RGCs observed in studies on histologic sections
of the optic nerve.24–26 The total number of RGCs in the optic
nerves of healthy donors was found to vary from 969,279 in
the study conducted by Mikelberg et al.24 to 1,244,005 in the
study of Balazsi et al.25 Also, our total number of estimated
RGC in glaucomatous eyes was similar to that found in other
studies with comparable MD SAP values, thus validating the
approach of estimating the RGC count using different types of
OCT instrument (654,706 RGCs, 687,219 RGCs, and 570,433
respectively, in our study, in Marvasti et al.13 and in Zhang et
al.22).
Because both total and macular estimated RGCs have a
significant linear inverse correlation with age, a thorough
analysis should take this factor in consideration when
searching for cutoffs between pathologic and healthy condi-
tions. This issue would call for an extremely articulate
approach: as an example, for the healthy group (r ¼ 0.46)
the regression coefficient suggests an average loss of approx-
imately 5000 to 6000 total RGC counts per year, but there are
two patients separated by more than 30 years of age (45 vs. 76
years) who share the same RGC count. The awareness of the
biological variability and of the peculiarity of each individual is
well known to challenge any generalization; at the same time
the use of paradigms and brackets of values are useful
stepping-stones for most diagnostic paths. All considered,
including the reduced sample size of our healthy group we
chose as feasible option a rough subdivision in two age
brackets (55 and >55 years).
The estimate of RGC count with the RTVue-100 performed
fairly well in distinguishing healthy from glaucomatous
(PPGþPOAG) eyes in both age brackets (AUC ¼ 0.80–0.92 for
the total estimated RGCs and AUC¼ 0.79–0.81 for the macular
estimated RGCs two age brackets) with no statistically
significant difference between total and macular estimated
RGCs.22 Our results are similar to the AUC values found by
Zhang et al.22 relative to all ages (AUC 0.93 and 0.87 for the
total and macular estimated RGC counts).
The approach showed a good discrimination also between
PPG and POAG eyes (AUC¼0.86–0.92) for all ages and for both
total and macular estimated RGC counts.
As expected, the discrimination between healthy and PPG
eyes was more arduous: the AUC for total estimated RGC count
ranged from 0.75 for ages below 55 years to 0.83 for ages above
55; for macular estimated RGC count, from 0.74 to 0.69. The
relatively lower ROC curve areas for these groups may reflect
the inaccuracy of PPG diagnosis. Some of the PPG eyes could
be actually normal; diagnosis of PPG is based on biomicrosco-
py of the ONH in the absence of VF loss, thus it would require
longitudinal follow-up for diagnostic confirmation.
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The inverse relation between age and RGCs number did not
significantly affect the discriminating ability of the test, the
comparison between the AUC values for the two brackets
leading to P values well above 0.05. The impact was instead
important on the determination of the cutoff values: the cut-
offs for people older than 55 years were found to be lower for
all cases. This means that a given total estimated RGC count
(for instance 1,000,000) lays below the 1,100,000 threshold for
glaucomatous (PPGþPOAG) eyes for a person younger than 55
years but above the 900,000 threshold for an older one. The
patient below 55 with RGC count ¼1,000,000 has a LR for
positive test LRþ ¼ 3.3, approximately 50% higher than the
FIGURE. On the left, the results obtained for the total estimated RGC count for patients older than 55 years when testing the discriminating ability
between healthy and glaucomatous eyes (PPGþPOAG). On the right, the results obtained for the total estimated RGC count for patients older than
55 years when testing the discriminating ability between PPG and POAG eyes. (A, D) Estimated RGC frequencies distributions. (B, E) ROC curves.
(C, F) Threshold determination.
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value 2.4 at the RCG ¼ 1,100,000 cutoff (i.e., a strong
indication for disease); the patient above 55 years with the
same RGC count has LRþ¼ 2.1, approximately 43% lower than
the value 3.7 at the cutoff, that is, even if we cannot radically
exclude disease (the healthy-disease distributions have a region
of overlapping) we can downgrade its possibility.
The LRþ, greater than 2 at cutoff and increasing up to two-
digit numbers as RGC values go beyond it, indicate the
appropriateness of this test and its contribution to the
diagnostic process for clinical decision-making in glaucoma.
In this sense, the estimated RCG count could work as a
biomarker.
Actually, the potential clinical applicability of the estimation
of RGC cells was already assessed by other studies, which
proved the usefulness of estimated RGC count for the
diagnosis, staging, and progression detection of the glaucoma-
tous damage. Gracitelli et al.27 used estimates of RGC counts
obtained by the same method used in the current study to
demonstrate that eyes with disc hemorrhages showed faster
rates of RGC loss compared with eyes without disc hemor-
rhages. The estimation of RGC cells was able to approximately
establish the intereye difference in RGCs number associated
with relative afferent papillary defect (RAPD).28 Meira-Freitas
et al.29 showed that baseline and longitudinal estimates of RGC
counts could predict future developments of VF loss or optic
disc damage in glaucoma suspect eyes. Patients with glau-
comatous progression during follow-up were detected with
higher accuracy using the estimated RGC count rather than
functional and structural evaluations separately considered.29
Furthermore in distinguishing glaucomatous from healthy eyes,
RGC count demonstrated to perform better than cup-to-disc
ratio (CDR), which has high intra- and interexaminer variability
and a relative insensitivity to evaluate glaucomatous progres-
sion.30 The estimated RGC count has also demonstrated the
large RGC loss associated with localized RNFL defects visible
on stereophotographs, usually considered one of the earliest
changes of POAG.31
The estimated RGC count may have a role also in the
interpretation of glaucomatous damage in the early stages.
There is evidence that a considerable amount of RGC loss
corresponds to a minimum change in visual field index (VFI) in
early stages of the disease. Marvasti et al.13 found that a change
of 0.3% in VFI in eyes with initial VFI of 100% would
correspond to a loss of 100,000 RGCs. Therefore, VFI
underestimates real neural loss, especially in initial phases of
disease. The results obtained in this study underline how a
change of 100,000 RGCs not only changes the probability of
disease, but also that the entity of the change varies with the
TABLE 2. Results of the ROC Curve Procedure for the Total Estimated RGC Count: AUC With 95% Confidence Intervals (95%CI) and Cutoff Values
With Relative SNS, SPC, and LRþ
Groups
Estimated Total RGC Count
AUC (95%CI) Cutoff (RGCs) SNS (%) SPC (%) LRþ
Healthy vs. PPGþPOAG
55 y 0.80 (0.69–0.90) 1,100,000 70.83 70.83 2.4
>55 y 0.92 (0.86–0.99) 900,000 100.00 73.12 3.7
PPG vs. POAG
55 y 0.92 (0.82–1) 900,000 87.18 80.00 4.4
>55 y 0.90 (0.83–0.96) 800,000 76.92 88.37 6.6
Healthy vs. PPG
55 y 0.75 (0.63–0.87) 1,100,000 70.83 64.10 2.0
>55 y 0.83 (0.71–0.94) 1,000,000 75.00 78.85 3.5
Healthy vs. POAG
55 y 0.99 (0.95–1) 1,000,000 100.00 90.00 10.0
>55 y 0.99 (0.98–1) 900,000 100.00 97.67 42.9
TABLE 3. Results of the ROC Curve Procedure for Macular Estimated RGC Count: AUC With 95% CI, Cutoff Values With Relative SNS, SPC, and LRþ
Groups
Estimated Macular RGC Count
AUC (95% CI) Cutoff (RGCs) SNS (%) SPC (%) LRþ
Healthy vs. PPGþPOAG
55 y 0.79 (0.68–0.90) 600,000 54.17 89.90 5.4
>55 y 0.81 (0.69–0.93) 500,000 75.00 77.89 3.4
PPG vs. POAG
55 y 0.88 (0.76–0.99) 500,000 76.92 90.00 7.7
>55 y 0.86 (0.79–0.93) 400,000 88.46 72.09 3.2
Healthy vs. PPG
55 y 0.74 (0.62–0.87) 600,000 54.17 87.18 4.2
>55 y 0.69 (0.51–0.87) 500,000 75.00 61.54 2.0
Healthy vs. POAG
55 y 0.96 (0.90–1) 500,000 95.83 90.00 9.6
>55 y 0.95 (0.89–1) 500,000 75.00 97.67 32.2
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estimated RGC number involved. Let us consider as an
example three patients over 55 years, for whom the divider
between healthy and pathologic conditions is 900,000 RGCs.
Let us further assume that the three patients have similar VFI
on SAP (100%, 97%, and 94%), but the first one scores 950,000
cells, the second 850,000, and the third one 750,000. The
100,000 RGCs difference between the first and the second
patient corresponds to an increase of LRþ from 2.7 to 5.8 (a 3-
fold increase of the probability of disease), whereas the very
same cells difference between the second and the third patient
corresponds to an increase of LRþ from 5.8 to 58 (a 10-fold
increase).
Considering the relationship between VF and RGC loss, our
study demonstrated that glaucomatous damage detectable with
SAP arises at an average percentage of 43% total estimated
ganglion cell loss and 41% macular estimated RGC loss. These
percentages are consistent with the conclusions of other
studies; Harwerth et al.32 stated that the percentage ganglion
cell loss associated with early VF defects is 50%, showing that a
20% to 50% loss of ganglion cells is required to produce a 6 dB
loss by static perimetry.33 According to other studies, at least
25% to 35% RGC loss is associated with abnormalities in
automated VF testing.34,35 However, some patients have
changes detected on visual field prior to detectable structural
changes and for this reason a combination of structural and
functional assessments are needed to provide optimal diagno-
sis of glaucoma.
Our study has some limitations. The number of RGCs is not
based on histologic data but is empirically derived from
formulas. However, such an estimation of RGC count was
shown to agree with histology in experimental glaucomas.9 We
are aware that the validation study of the formula for estimating
RGC number used time-domain OCT,9 however subsequent
studies applying FD-OCT assessed the accuracy and validity of
the formulas.10–14 A possible cause of inaccuracy in estimating
the total number of RGCs with the formula described by
Medeiros et al.10 lies in the different areas analyzed through
OCT and SAP. Average RNFL thickness (measured by OCT)
takes into account the entire region around the optic disc,
corresponding to the RGCs of the entire retina; the 24-2 VF, on
the contrary, analyses approximately 6278 of visual angle from
the fovea.36 This disagreement is consistent with the conclu-
sions of Raza and Hood.37 This limitation, however, may not
preclude the clinical usefulness of the method, as demonstrat-
ed by the present study and by several others.10–14,27–31 The
estimate of macular RGCs underlines a further limitation: the
macular estimated RGC count could be affected by macular
diseases. An accurate macular examination is therefore
necessary to exclude any macular affection. Another limitation
of the study was the use of the median value of 55 years for
dividing our population in two age brackets.
In conclusion, our study confirms that RGC count estimated
with empirical formulas with RTVue-100 can be used as a valid
surrogate for neural losses in glaucoma. The determination of
the threshold markers of the estimated RGC number and the
use of LRs that take into account the age, could improve early
diagnosis and management of glaucoma. The results of the
present study, added to the considerable amount of previous
works substantiating the clinical applicability, suggest that the
estimated RGC count could well be taken into consideration as
candidate biomarker for diagnosis and early detection of
glaucoma progression.
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